These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37548458)

  • 21. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.
    Krysiak R; Gdula-Dymek A; Okopien B
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1109-17. PubMed ID: 21630032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD).
    Seki M; Nakano T; Tanaka S; Matsukuma Y; Funakoshi K; Ohkuma T; Kitazono T
    Clin Exp Nephrol; 2023 Apr; 27(4):358-364. PubMed ID: 36738362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
    Broeders N; Knoop C; Antoine M; Tielemans C; Abramowicz D
    Nephrol Dial Transplant; 2000 Dec; 15(12):1993-9. PubMed ID: 11096145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice.
    Iitake C; Iitake K
    J Clin Med Res; 2019 Oct; 11(10):690-695. PubMed ID: 31636783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus.
    Yamaguchi T; Shirai K; Nagayama D; Nakamura S; Oka R; Tanaka S; Watanabe Y; Imamura H; Sato Y; Kawana H; Ohira M; Saiki A; Shimizu N; Tatsuno I
    J Atheroscler Thromb; 2019 Jul; 26(7):659-669. PubMed ID: 30584220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
    Komiya I; Yamamoto A; Sunakawa S; Wakugami T
    Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial.
    Bastow MD; Durrington PN; Ishola M
    Metabolism; 1988 Mar; 37(3):217-20. PubMed ID: 3278190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of pleiotropic effects of statins vs fibrates on laboratory parameters in patients with dyslipidemia: A retrospective cohort study.
    Takeuchi S; Takahashi Y; Asai S
    Medicine (Baltimore); 2020 Dec; 99(50):e23427. PubMed ID: 33327270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
    Raposo HF; Patrício PR; Simões MC; Oliveira HC
    J Nutr Biochem; 2014 Jun; 25(6):669-74. PubMed ID: 24746832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
    N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
    Iitake C; Masuda D; Koseki M; Yamashita S
    Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of fibrates in cholestatic liver diseases.
    Carrion AF; Lindor KD; Levy C
    Liver Int; 2021 Jun; 41(6):1335-1343. PubMed ID: 33751787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
    Spieker LE; Noll G; Hannak M; Lüscher TF
    J Cardiovasc Pharmacol; 2000 Mar; 35(3):361-5. PubMed ID: 10710119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia.
    Jonkers IJ; de Man FH; van der Laarse A; Frölich M; Gevers Leuven JA; Kamper AM; Blauw GJ; Smelt AH
    J Hypertens; 2001 Apr; 19(4):749-55. PubMed ID: 11330878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.
    Saito Y; Yamada N; Shirai K; Sasaki J; Ebihara Y; Yanase T; Fox JC
    Atherosclerosis; 2007 Oct; 194(2):505-11. PubMed ID: 17223112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibric acids: effects on lipids and lipoprotein metabolism.
    Grundy SM; Vega GL
    Am J Med; 1987 Nov; 83(5B):9-20. PubMed ID: 3318457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.